Skip to main content

Novartis AG (NVS) Stock Forecast

Data as of Aug 1, 2026

Healthcare · Current price $156.57 (-1.10%)

Consensus Target
$170.00
Upside
+8.6%
Analysts
1
Rating
Hold(3.00)

Price Target Range

Low $170.00High $170.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

NVS vs Sector & Market

MetricNVSHealthcare AvgLarge Cap Avg
Analyst Rating3.002.252.42
Analyst Count1819
Target Upside+8.6%+16316.2%+17.1%
P/E Ratio19.862.9943.33

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$14.15B$14.52B$14.77B2
2026-12-31$14.39B$14.77B$15.02B3
2027-03-31$13.46B$13.82B$14.05B3
2027-06-30$14.03B$14.40B$14.64B2
2027-09-30$14.26B$14.63B$14.88B2
2027-12-31$14.37B$14.76B$15.00B3

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$2.19$2.26$2.311
2026-12-31$2.11$2.19$2.231
2027-03-31$2.17$2.25$2.301
2027-06-30$2.29$2.37$2.421
2027-09-30$2.33$2.41$2.461
2027-12-31$2.34$2.42$2.471

Frequently Asked Questions

What is the analyst consensus for NVS?

The consensus among 1 analysts covering Novartis AG (NVS) is Hold with an average price target of $170.00.

What is the highest price target for NVS?

The highest analyst price target for NVS is $170.00.

What is the lowest price target for NVS?

The lowest analyst price target for NVS is $170.00.

How many analysts cover NVS?

1 analysts have issued ratings for Novartis AG in the past 12 months.

Is NVS a buy or sell right now?

Based on 1 analyst ratings, NVS has a consensus rating of Hold (3.00/5) with a +8.6% upside to the consensus target of $170.00.

What are the earnings estimates for NVS?

Analysts estimate NVS will report EPS of $2.26 for the period ending 2026-09-30, with revenue estimated at $14.52B.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.